Comparison of the effectiveness of Beraksurf and Curosurf exogenous surfactants in the treatment of respiratory distress syndrome in preterm infants

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200812048381N1

Enrollment

140

Registered

2021-04-04

Start date

2021-04-20

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome. Respiratory distress syndrome of newborn

Interventions

Intervention group: All premature infants with inclusion criteria and no exclusion criteria, hospitalized in Fatemieh and Besat hospitals in Hamedan in 1399 and 1400. Broxurf surfactant, made in Iran

Eligibility

Sex/Gender

All

Age

196 Days to 252 Days

Inclusion criteria

Inclusion criteria: Premature infants 28 to 36 weeks with respiratory distress syndrome Hospitalized in Fatemieh or Besat Hospital Need for insure treatment with surfactant during the first 24 hours of life Apgar fifth minute more than 5

Exclusion criteria

Exclusion criteria: Need a ventilator from the beginning of hospitalization Existence of other respiratory diseases other than respiratory distress syndrome Congenital heart malformations, other major congenital malformations

Design outcomes

Primary

Measure	Time frame
Injection of surfactant at a dose of 100 mg / kg by intubation into the lungs under sterile conditions and by drip into the tube. Timepoint: During the first 24 hours of life. Method of measurement: Is it necessary to re-intubate within 72 hours after receiving the surfactant?.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfatemeh eghbalian

Hamedan University of Medical Sciences

eghbalian_fa@yahoo.com+98 918 119 0121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026